Table 2 Generalized estimating equation (GEE) models to evaluate the effects of Levothyroxine replacement therapy (LRT) on inflammatory, oxidative stress, hemoglobin, and lipid profile parameters of hypothyroid patients

TSH (μIU/mL)

32.4 (18.0–30.4)

20.7 (8.6–49.8)

10.5 (6.3–17.4)

18.496

2

<0.0001

FT4 (ng/dL)

0.8 (0.7–0.9)

3.4 (1.8–6.6)

2.7 (1.3–5.8)

33.684

2

<0.0001

IL-10 (pg/mL)

132.7 (124.5–141.0)

160.7 (150.7–170.6)

184.6 (174.8–194.4)

181.076

2

<0.0001

IL-1 (pg/mL)

73.0 (68.5–77.4)

57.9 (52.6–63.1)

45.0 (40.4–49.6)

321.214

2

<0.0001

IL-6 (pg/mL)

90.1 (83.7–96.4)

70.5 (63.9–77.1)

49.9 (44.1–55.6)

512.104

2

<0.0001

INF-γ (pg/mL)

144.8 (141.0–148.6)

98.6 (93.1–104.5)

80.0 (75.8–84.3)

386.001

2

<0.0001

TNF-α (pg/mL)

122.8 (120.5–125.1)

90.4 (86.8–94.0)

66.2 (61.6–71.1)

341.402

2

<0.0001

hs-CRP (mg/dl)

0.6 (0.3–1.1)

0.5 (0.3–0.8)

0.9 (0.5–1.7)

2.519

2

0.284

NP-SH (nmol NP - SH/mL erit)

1522.4 (1374.9–1670.0)

1098.1 (929.3–1267.0)

1004.6 (757.5–1251.7)

23.528

2

<0.0001

Total-SH (nmol T -SH/ml plasma)

823.3 (683.5–963.2)

624.0 (537.1–710.8)

660.5 (584.2–772.8)

5.388

2

0.068

δ-ALA-D (nmol PBG/hour/ml of blood)

3.6 (2.7–4.4)

3.1 (1.9–4.3)

3.0 (2.1–4.0)

0.644

2

0.725

TBARS (nmol MDA/mL erit)

5.3 (4.0–6.7)

7.2 (4.8–8.5)

6.7 (4.8–8.5)

2.862

2

0.239

Hemoglobin (g/dL)

13.1 (12.6–13.6)

13.4 (13.0–13.9)

13.6 (13.2–14.0)

8.252

2

0.016

TC (mg/dL)

201.5 (176.7–244.2)

198.4 (168.5–228.4)

198.4 (171.9–225.0)

1.567

2

0.457

HDL- C (mg/dL)

54.3 (48.8–59.7)

50.9 (41.8–60.0)

52.1 (45.8–58.4)

0.670

2

0.715

LDL- C (mg/dL)

124.2 (102.6–150.5)

115.5 995.5–139.7)

115.5 (99.0–134.7)

2.146

2

0.342

TG (mg/dL)

117.5 (88.1–156.9)

139.2 (99.2–195.4)

119.6 (85.3–167.7)

1.085

2

0.581